RNXT logo

RENOVORX INC

RNXTNASDAQ
🏆 #4280 by market capEarnings Nov 11US Equity
$1.57▲ $0.01 (+0.64%)
Market closed · at close
🔔
Track RNXT
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.6%
7d▼ 4.3%
14d▲ 1.0%
30d▼ 19.5%
ytd▲ 85.9%
1y▲ 24.1%
🏦Market Cap
$71M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
84.4%
High
💵FCF Margin
—
⚖️P/S Ratio
35.9x
Expensive
Otter Score
76
Good

Trading Snapshot

Day Range
$1.55 – $1.59
52-Week Range
$0.70 – $2.59
Volume
$2.01B
Avg Volume
$1.65B
Shares Outstanding
45.0M
Next Earnings
Nov 12, 2026

Fundamentals Snapshot

Annual Revenue
$1M
Last Q Revenue
$909,000
P/E Ratio
—
P/S Ratio
35.9x
EPS (TTM)
$-0.31
Dividend Yield
—
Dilution (1yr)
+58.6%

Why Investors Own RNXT

  • ✓High-growth profile — revenue up +23.1% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 61% gross margin and 25% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

RNXT logo

RENOVORX INC

RNXT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1M▲ +2511.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
70.9%▼ −29.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$13M▲ +14.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$11M▲ +20.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
35.3M▲ +58.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$7M▼ −$64K YoY
StockOtter · stockotter.space

About RENOVORX INC

RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
76/100

Analyst Price Target

ⓘ
Average Target
$1.74
▲ +10.7% Upside
High Target$2.14
Low Target$1.30
Based on 39 analysts

Latest News & Updates

🚀
Barron’s·2h ago

RENOVORX INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift RNXT price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

RENOVORX INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.